5,031 results on '"Biological products industry -- Product development"'
Search Results
2. Genethon and Hansa Initiate Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
3. Genethon and Hansa Initiate Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
4. Genethon & Hansa begin phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
5. Genethon and Hansa Initiate Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
6. Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836
7. LakeShore`s YSJA rabies vaccine receives approval for Phase III trial in China
8. Cyclacel reports clinical data from Phase 2 study of oral fadraciclib
9. Gilead & Merck announce phase 2 data showing a treatment switch to an investigational oral once-weekly combination regimen of islatravir & lenacapavir maintained viral suppression in adults at week 48
10. Kiromic BioPharma: Deltacel-01 to Enter Expansion Phase Following SMC's Unanimous Recommendation
11. CD (Suzhou) Biopharma gets US FDA clearance to begin phase I trial of CD-001
12. Palatin: FDA confirms acceptability of Phase 3 pivotal clinical trials for PL964
13. Artax Biopharma completes patient recruitment in phase 2a trial with AX-158 for autoimmune diseases
14. Application for clinical trial of AIM Vaccine’s human diploid rabies vaccine
15. GT Biopharma announces FDA clearance of IND application for GTB-3650
16. Kiromic BioPharma provides updates on its Deltacel-01 clinical trial
17. Palatin initiates Phase 2 clinical study of bremelanotide
18. US clinical trials begin for twice-yearly HIV prevention injection
19. Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
20. The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science
21. Ascites Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis
22. SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
23. Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
24. Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
25. Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
26. Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXelleratetm
27. Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
28. Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
29. PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen
30. Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
31. PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen
32. Brazil suspends development of its anticovirus vaccine after failing human trials
33. Biological E announces positive results from phase-III trials of Pneubevax 14 in 6-8-week old infants
34. YS Biopharma: YS-HBV-002 vaccine granted clinical trial approval by PFDA
35. YS Biopharma's PIKA Rabies Vaccine meets Phase 3 primary endpoints
36. Palatin presents results from Phase 3 PL9643 MELODY-1 trial
37. Can-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson
38. Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044
39. Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044
40. Genethon and Hansa Initiate Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
41. Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome
42. Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome
43. Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome
44. Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
45. Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
46. LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
47. Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc
48. Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
49. Pressure Ulcers Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Xantho Biotechnology, Biocomposites Ltd, RegeneRx Biopharma, B. Braun
50. Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.